Increased Renal Versican Expression Is Associated with Progression of Chronic Kidney Disease

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Rudnicki, Michael ^a   Perco, Paul ^b   Neuwirt, Hannes ^a   Noppert, Susie Jane ^a   Leierer, Johannes ^a   Sunzenauer, Judith ^a   Eder, Susanne ^a   Zoja, Carlamaria ^c   Eller, Kathrin ^a,d   Rosenkranz, Alexander R ^a,d   Müller, Gerhard A ^e   Mayer, Bernd ^b   Mayer, Gert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Emergentec Biodevelopment GmbH   (Austria)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ISOPROTEIN; RNA; UNCLASSIFIED DRUG; VERSICAN; VERSICAN ISOFORM V0; VERSICAN ISOFORM V1; VERSICAN ISOFORM V2; VERSICAN ISOFORM V3;

ACUTE KIDNEY FAILURE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBROBLAST; FOLLOW UP; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; RAT; REGULATORY MECHANISM; SCORING SYSTEM; TRANSCRIPTOMICS; UPREGULATION;

RODENTIA;

EID: 84866360732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044891     Document Type: Article

References (37)

1. Meguid El Nahas A, Bello AK, (2005) Chronic kidney disease: the global challenge. Lancet 365: 331-340.
2. D'Amico G, (1992) Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 20: 315-323.
3. Hladunewich MA, Troyanov S, Calafati J, Cattran DC, (2009) The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422.
4. Reich HN, Troyanov S, Scholey JW, Cattran DC, (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183.
5. Meyer TW, (2003) Tubular injury in glomerular disease. Kidney Int 63: 774-787.
6. Kronenberg F, (2009) Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 5: 677-689.
7. Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, et al. (2004) Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 65: 904-917.
8. Perco P, Kainz A, Wilflingseder J, Soleiman A, Mayer B, et al. (2009) Histogenomics: association of gene expression patterns with histological parameters in kidney biopsies. Transplantation 87: 290-295.
9. Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, et al. (2009) Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 89: 337-346.
10. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, et al. (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55: 2993-3003.
11. Dours-Zimmermann MT, Zimmermann DR, (1994) A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 269: 32992-32998.
12. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, et al. (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8: 1054-1060.
13. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, et al. (2001) Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 61: 926-930.
14. Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, et al. (2006) Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58: 47-53.
15. Dours-Zimmermann MT, Maurer K, Rauch U, Stoffel W, Fassler R, et al. (2009) Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J Neurosci 29: 7731-7742.
16. Miquel-Serra L, Serra M, Hernandez D, Domenzain C, Docampo MJ, et al. (2006) V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest 86: 889-901.
17. Theocharis AD, (2008) Versican in health and disease. Connect Tissue Res 49: 230-234.
18. Wight TN, Merrilees MJ, (2004) Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 94: 1158-1167.
19. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, et al. (1998) Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971.
20. Melk A, Mansfield ES, Hsieh SC, Hernandez-Boussard T, Grimm P, et al. (2005) Transcriptional analysis of the molecular basis of human kidney aging using cDNA microarray profiling. Kidney Int 68: 2667-2679.
21. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, et al. (2010) A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 120: 1862-1872.
22. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, et al. (1996) Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 44: 303-312.
23. True LD, Hawley S, Norwood TH, Braun KR, Evanko SP, et al. (2009) The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate 69: 149-158.
24. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, et al. (2006) Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 17: 2009-2020.
25. Sheng W, Wang G, Wang Y, Liang J, Wen J, et al. (2005) The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 16: 1330-1340.
26. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, et al. (2000) Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 275: 35448-35456.
27. Hirose J, Kawashima H, Yoshie O, Tashiro K, Miyasaka M, (2001) Versican interacts with chemokines and modulates cellular responses. J Biol Chem 276: 5228-5234.
28. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB, (2005) The interaction of versican with its binding partners. Cell Res 15: 483-494.
29. Schuttert JB, Liu MH, Gliem N, Fiedler GM, Zopf S, et al. (2003) Human renal fibroblasts derived from normal and fibrotic kidneys show differences in increase of extracellular matrix synthesis and cell proliferation upon angiotensin II exposure. Pflugers Arch 446: 387-393.
30. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, et al. (2006) hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer research 66: 3531-3540.
31. Massoner P, Haag P, Seifarth C, Jurgeit A, Rogatsch H, et al. (2008) Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction. The Prostate 68: 1165-1178.
32. Klocker H, Kaspar F, Eberle J, Uberreiter S, Radmayr C, et al. (1992) Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. American journal of human genetics 50: 1318-1327.
33. Rosenkranz AR, Mendrick DL, Cotran RS, Mayadas TN, (1999) P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 103: 649-659.
34. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, et al. (2002) How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. Journal of the American Society of Nephrology: JASN 13: 2898-2908.
35. Remuzzi G, Zoja C, Remuzzi A, Rossini M, Battaglia C, et al. (1985) Low-protein diet prevents glomerular damage in adriamycin-treated rats. Kidney international 28: 21-27.
36. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, et al. (2010) Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. American journal of physiology Renal physiology 299: F1203-1211.
37. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, et al. (2006) Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. The American journal of pathology 169: 2199-2208.